10% original issue discount 5% Senior Convertible NOTE DUE November 25, 2019OncBioMune Pharmaceuticals, Inc • April 1st, 2019 • Pharmaceutical preparations • New York
THIS 10% SENIOR CONVERTIBLE NOTE is one of a series of duly authorized and validly issued 5% Senior Convertible Notes issued at a 10% original issue discount by OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”) (this note, the “Note” and, collectively with the other notes of such series, the “Notes”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 1st, 2019 • OncBioMune Pharmaceuticals, Inc • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of March 25, 2019, between OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and Cavalry Fund I LP (the “Purchaser”).
COMMON STOCK PURCHASE WARRANT OncBioMune Pharmaceuticals, Inc.OncBioMune Pharmaceuticals, Inc • April 1st, 2019 • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Cavalry Fund I LP, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five (5) year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), up to 2,083,333 shares of Common Stock (subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
EMPLOYMENT AGREMENTOncBioMune Pharmaceuticals, Inc • April 1st, 2019 • Pharmaceutical preparations • Louisiana
AND: OncBioMune Pharmaceuticals, Inc. (the “Company”), an entity organized and existing under the laws of the State of Nevada, with its head office located at:
